Literature DB >> 25124092

Pelvic organ prolapse surgical management in Portugal and FDA safety communication have an impact on vaginal mesh.

Teresa Mascarenhas1, Miguel Mascarenhas-Saraiva, Amélia Ricon-Ferraz, Paula Nogueira, Fernando Lopes, Alberto Freitas.   

Abstract

INTRODUCTION AND HYPOTHESIS: Pelvic organ prolapse (POP) surgery has lately gained importance in gynecological practice. This study aims to characterize the evolution of POP surgical procedures conducted in Portugal in the last decade and the impact of an FDA 2011 safety communication on mesh POP surgeries.
METHODS: Trends in the surgical management of POP were assessed using the Portuguese National Medical Registry. We considered all records of women with diagnosis of genital prolapse from 1 January 2000 to 31 December 2012. Additionally, we also conducted a survey among members of the Portuguese Society of Urogynecology to evaluate current practices in the surgical management of POP.
RESULTS: From 2000 to 2012, 46,819 diagnoses of genital prolapse were registered, with a 105 % increase during the study period (2,368 in 2000 to 4,941 in 2012). POP mesh surgery represented only 6 % of total prolapse diagnoses, but mesh use greatly increased up to 2011, when only a slight increase was registered. Among gynecologists who responded to the questionnaire, there was considerable variability on the procedures of choice to treat POP. Fifty-seven per cent of respondents performed vaginal mesh POP surgery, but only 27 % of those actually reported having changed their practice after the FDA 2011 safety communication.
CONCLUSIONS: Surgical procedures for POP conducted in Portugal greatly increased over the last decade. The use of surgical meshes is still limited, but despite FDA safety communication it has increased over the years, with a slight increase in 2012, which illustrates the need for further analyses in the coming years.

Entities:  

Mesh:

Year:  2014        PMID: 25124092     DOI: 10.1007/s00192-014-2480-0

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  23 in total

1.  Lifetime risk of undergoing surgery for pelvic organ prolapse.

Authors:  Fiona J Smith; C D'Arcy J Holman; Rachael E Moorin; Nicolas Tsokos
Journal:  Obstet Gynecol       Date:  2010-11       Impact factor: 7.661

2.  Impact of the 2011 FDA transvaginal mesh safety update on AUGS members' use of synthetic mesh and biologic grafts in pelvic reconstructive surgery.

Authors:  Jeffrey L Clemons; Milena Weinstein; Marsha K Guess; Marianna Alperin; Pamela Moalli; William Thomas Gregory; Emily S Lukacz; Vivian W Sung; Bertha H Chen; Catherine S Bradley
Journal:  Female Pelvic Med Reconstr Surg       Date:  2013 Jul-Aug       Impact factor: 2.091

Review 3.  ICI 2012: pelvic organ prolapse surgery.

Authors:  Christopher Maher
Journal:  Int Urogynecol J       Date:  2013-11       Impact factor: 2.894

4.  The UK national prolapse survey: 5 years on.

Authors:  Swati Jha; Paul Moran
Journal:  Int Urogynecol J       Date:  2011-02-22       Impact factor: 2.894

5.  An appraisal of the Food and Drug Administration warning on urogynecologic surgical mesh.

Authors:  Lindsey C Menchen; Alan J Wein; Ariana L Smith
Journal:  Curr Urol Rep       Date:  2012-06       Impact factor: 3.092

6.  Trends in various types of surgery for hysterectomy and distribution by patient age, surgeon age, and hospital accreditation: 10-year population-based study in Taiwan.

Authors:  Ming-Ping Wu; Kuan-Hui Huang; Cheng-Yu Long; Eing-Mei Tsai; Chao-Hsiun Tang
Journal:  J Minim Invasive Gynecol       Date:  2010-07-24       Impact factor: 4.137

7.  Shifts in national rates of inpatient prolapse surgery emphasize current coding inadequacies.

Authors:  Sarah L Bradley; Alison C Weidner; Nazema Y Siddiqui; Mihir P Gandhi; Jennifer M Wu
Journal:  Female Pelvic Med Reconstr Surg       Date:  2011-07       Impact factor: 2.091

8.  Changes in prolapse surgery trends relative to FDA notifications regarding vaginal mesh.

Authors:  Laura C Skoczylas; Lindsay C Turner; Li Wang; Daniel G Winger; Jonathan P Shepherd
Journal:  Int Urogynecol J       Date:  2013-10-01       Impact factor: 2.894

Review 9.  Where to for pelvic organ prolapse treatment after the FDA pronouncements? A systematic review of the recent literature.

Authors:  J M van Geelen; P L Dwyer
Journal:  Int Urogynecol J       Date:  2013-01-10       Impact factor: 2.894

Review 10.  The role of vaginal mesh procedures in pelvic organ prolapse surgery in view of complication risk.

Authors:  David R Ellington; Holly E Richter
Journal:  Obstet Gynecol Int       Date:  2013-08-28
View more
  2 in total

1.  Trends in prolapse surgery in England.

Authors:  Martino Maria Zacche; Sambit Mukhopadhyay; Ilias Giarenis
Journal:  Int Urogynecol J       Date:  2018-08-04       Impact factor: 2.894

Review 2.  Epidemiological trends and future care needs for pelvic floor disorders.

Authors:  Alexis A Dieter; Maggie F Wilkins; Jennifer M Wu
Journal:  Curr Opin Obstet Gynecol       Date:  2015-10       Impact factor: 1.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.